Search Results - "Ragozzino, Forrest J"

Circadian regulation of glutamate release pathways shapes synaptic throughput in the brainstem nucleus of the solitary tract (NTS) by Ragozzino, Forrest J., Peterson, Bree Anne, Karatsoreos, Ilia N., Peters, James H.

“…Circadian regulation of autonomic reflex pathways pairs physiological function with the daily light cycle. The brainstem nucleus of the solitary tract (NTS) is…”
Get full text

Principles of synaptic encoding of brainstem circadian rhythms by Ragozzino, Forrest J, Karatsoreos, Ilia N, Peters, James H

“…Circadian regulation of autonomic tone and reflex pathways pairs physiological processes with the daily light cycle. However, the underlying mechanisms…”
Get full text

Corticosterone inhibits vagal afferent glutamate release in the nucleus of the solitary tract via retrograde endocannabinoid signaling by Ragozzino, Forrest J, Arnold, Rachel A, Kowalski, Cody W, Savenkova, Marina I, Karatsoreos, Ilia N, Peters, James H

“…Circulating blood glucocorticoid levels are dynamic and responsive to stimuli that impact autonomic function. In the brain stem, vagal afferent terminals…”
Get more information

TRPM3 expression and control of glutamate release from primary vagal afferent neurons by Ragozzino, Forrest J, Arnold, Rachel A, Fenwick, Axel J, Riley, Timothy P, Lindberg, Jonathan E M, Peterson, BreeAnne, Peters, James H

“…Vagal afferent fibers contact neurons in the nucleus of the solitary tract (NTS) and release glutamate via three distinct release pathways: synchronous,…”
Get full text

Cannabidiol activation of vagal afferent neurons requires TRPA1 by Kowalski, Cody W., Ragozzino, Forrest J., Lindberg, Jonathan E. M., Peterson, BreeAnne, Lugo, Janelle M., McLaughlin, Ryan J., Peters, James H.

“…Cannabidiol is legal in many US states and is used as a panacea for a host of different symptoms; however, little research has been conducted on its cellular…”
Get full text

The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1 by Fortin, Samantha M., Chen, Jack C., Petticord, Marisa C., Ragozzino, Forrest J., Peters, James H., Hayes, Matthew R.

“…Increasing the therapeutic potential and reducing the side effects of U.S. Food and Drug Administration–approved glucagon-like peptide-1 receptor (GLP-1R)…”
Get full text